Charting Only, page-468

Can it be catastrophic for one yet, not the other? Isn't the success or failure of both linked?

Or did you just want to wonder by and talk sh@t?

Biotech is a fickle place. Some years ago, I was buying RAC at 15c. Starting selling them at $2.50 with the last sale at $3.10. Did the same with IMU buying at 1c and selling between 45c and 48c. IHL in at 3c out at 22c.
I used preset trailing sells to make sure greed didn't keep me locked in. Sold both because the market cap was too high for where the company was at.

Now CHM is a bit different. Its a much higher risk investment due to finances. But the Market cap allows for a much greater potential future gain. There is no EV value in the present market cap. For me, this helps make the risk worth it.

But this certainly isnt for everybody. And the future will be a rocky one for a while. But with 4 trials hitting arms and things progressing well (even with new trial design for GBM) they just need to keep the pipeline progressing.

Your mate Hopper just threw another million dollars into the pot to keep that happening. He has put his and his families money into CHM. He sourced the drugs for the pipeline. All new, all novel and all first in class. So although he has a dodgy haircut, he is willing to put his money in to support the company.